Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2020 Dec 1;59(12):3727-3730.
doi: 10.1093/rheumatology/keaa118.

Long-term outcomes and disease course of children with juvenile idiopathic arthritis in the ReACCh-Out cohort: a two-centre experience

Amieleena Chhabra  1   2 , Cal Robinson  3   4 , Kristin Houghton  1   2 , David A Cabral  1   2 , Kimberly Morishita  1   2 , Lori B Tucker  1   2 , Ross E Petty  1   2 , Maggie Larché  3 , Michelle Batthish  3   4 , Jaime Guzman  1   2
Affiliations
Multicenter Study

Long-term outcomes and disease course of children with juvenile idiopathic arthritis in the ReACCh-Out cohort: a two-centre experience

Amieleena Chhabra et al. Rheumatology (Oxford). .

Abstract

Objective: To assess long-term outcomes of children with JIA diagnosed in the biologic era.

Methods: Chart review of patients prospectively enrolled in the Research in Arthritis in Canadian Children Emphasizing Outcomes inception cohort at two Canadian centres. Inactive disease and remission were defined according to Wallace criteria.

Results: We included 247 of 254 (97%) eligible patients diagnosed 2005-10. At the last follow-up visit at a median age of 16.9 years, 47% were in remission off medications, 25% in remission on medications and 27% had active disease; 51% were on at least one anti-rheumatic medication (22% on biologics). Patients with systemic JIA had the highest frequency of remission off medications (70%) and patients with RF-positive polyarthritis had the lowest (18%) (P <0.05 by Fisher's exact test). Among 99 patients with oligoarthritis at enrolment, 14 (14%) had an oligoarthritis extended course. Forty-five patients (18%) had at least one erosion or joint space narrowing in X-rays or MRI, and two (0.8%) required joint replacement.

Conclusion: Relative to historical cohorts, this study suggests a reduction in JIA permanent damage, a more favourable prognosis for systemic JIA and a lower progression to oligoarthritis extended category. However, in an era of biologic therapy, one in four patients with JIA still enter adulthood with active disease and one in two still on treatment.

Keywords: biological therapy; juvenile idiopathic arthritis; prognosis.

PubMed Disclaimer

Figures

<sc>Fig</sc>. 1
Fig. 1
Disease status at the last available visit The clinical charts of 247 children with juvenile idiopathic arthritis diagnosed 2005–10 at two Canadian centres were reviewed in 2018, at the last available visit before discharge or transition to adult care. Active disease, remission on medications and remission off medications were defined as per Wallace criteria [7]. JI: joint injections with corticosteroids.
See this image and copyright information in PMC

References

    1. Ruperto N, Levinson JE, Ravelli A. et al. Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. I. Outcome status. J Rheumatol 1997;24:945–51. - PubMed
    1. Gäre BA, Fasth A.. The natural history of juvenile chronic arthritis: a population-based cohort study. II. Outcome. J Rheumatol 1995;22:308–19. - PubMed
    1. Oen K, Malleson PN, Cabral DA. et al. Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. JRheumatol 2002;29:1989–99. - PubMed
    1. Ravelli A, Consolaro A, Horneff G. et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis 2018;77:819–28. - PubMed
    1. van Dijkhuizen EH, Wulffraat NM.. Early predictors of prognosis in juvenile idiopathic arthritis: a systematic literature review. Ann Rheum Dis 2015;74:1996–2005. - PubMed

Publication types

Substances